NLS Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   0 Trials   11 News 
  • ||||||||||  Quilience (mazindol CR) / NLS Pharma, mazindol controlled release (NLS-2) / NLS Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  AMAZE: A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (clinicaltrials.gov) -  May 20, 2024   
    P3,  N=48, Not yet recruiting, 
    This work subscribes to the effort to clarify the intricate relationships between nuclear transporters and their cargo proteins, in order to better understand the mechanism of nuclear transport of proteins and lay the groundwork for the development of novel therapeutics that target particular importins and have an immediate translational impact. Trial completion date: Feb 2025 --> Jul 2025 | Initiation date: Jan 2024 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2025
  • ||||||||||  Quilience (mazindol CR) / NLS Pharma, mazindol controlled release (NLS-2) / NLS Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  AMAZE: A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (clinicaltrials.gov) -  Nov 13, 2023   
    P3,  N=48, Not yet recruiting, 
    The 16S rRNA gene and genome sequences of strain NLS-7 have been deposited in GenBank under accession numbers ON715489 and GCA_024448135.1, respectively. Trial completion date: Aug 2024 --> Feb 2025 | Initiation date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2024 --> Jan 2025
  • ||||||||||  NLS-8 / NLS Pharma
    Effects of NLS-8 (Melafenoxate) on Memory in a Model of Alzheimer (Salon 4) -  Apr 15, 2023 - Abstract #ASCP2023ASCP_264;    
    These effects were significant at doses of 50 and 150 mg/kg and was close to significant at the dose of 100 mg/kg. Learning Objectives Describe the specific pharmacology of NLS-8 Describe the process by which NLS-8 is developed
  • ||||||||||  lauflumide (NLS-4) / NLS Pharma
    Effects of NLS-4 (lauflumide) and Modafinil in a Rat Model of Chronic Severe Fatigue (Salon 4) -  Apr 15, 2023 - Abstract #ASCP2023ASCP_263;    
    Since modafinil has been shown to improve recovery from chronic fatigue in human, these results suggest that NLS-4 could improve recovery from CFS in human at doses four times lower than those used for modafinil. Learning Objectives Describe the specific pharmacology of NLS-4 Describe the process by which NLS-4 is developed
  • ||||||||||  NLS-11 / NLS Pharma
    Effects of NLS-11 (Benedin) on Memory in the Novel Object Recognition Test in Mice (Salon 4) -  Apr 15, 2023 - Abstract #ASCP2023ASCP_204;    
    At doses tested, NLS-11 did not reduce exploratory behavior, contrary to donepezil, suggesting that NLS-11 may induce less side effects than donepezil. Learning Objectives Describe the specific pharmacology of NLS-4 Describe the process by which NLS-4 is developed
  • ||||||||||  Quilience (mazindol CR) / NLS Pharma, mazindol controlled release (NLS-2) / NLS Pharma
    Trial completion:  An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy (clinicaltrials.gov) -  Mar 13, 2023   
    P2,  N=52, Completed, 
    Learning Objectives Describe the specific pharmacology of NLS-4 Describe the process by which NLS-4 is developed Active, not recruiting --> Completed
  • ||||||||||  NLS-7 / NLS Pharma
    Isolation Of Five Novel Methane Oxidizing Bacteria From The Deep Terrestrial, A Freshwater Creek, And Landfill Cover Soil (Exhibit and Poster Hall) -  Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_3402;    
    We have also isolated a novel species of the genus Methylocystis (NLS-7) from landfill cover soil in Norman, OK, USA...Once characterized, it will also be the only formally characterized species of Methylocystis to be isolated from landfill cover soil. MOB are critical to the function of methane-producing ecosystems and this work highlights the biodiversity of these ecosystems while enriching our understanding of MOB ecology.
  • ||||||||||  Clinical, Review, Journal:  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. (Pubmed Central) -  Sep 21, 2020   
    Due to the absence of or limitations in the data, no comments for clinicians can be provided on the pharmacokinetic DDIs for clonidine, centanafadine, mazindol, molindone, AR-08, P. tenuifolia extract and the French maritime pine bark extracts...A summary table for clinicians provides our current recommendations on pharmacokinetic DDIs of ADHD agents based on our literature review and the package inserts; whenever it was possible, we provide information on serum concentrations and dose correction factors. There will be a need to periodically update these recommendations and these correction factors as new knowledge becomes available.
  • ||||||||||  phacetoperane (NLS-3) - NLS / 1 Pharma
    Journal, Head-to-Head:  Ezrin interacts with L-periaxin by the "head to head and tail to tail" mode and influences the location of L-periaxin in Schwann cell RSC96. (Pubmed Central) -  Sep 16, 2020   
    In the present study, we observed that L-periaxin and ezrin interacted in a "head to head and tail to tail" mode in SC RSC96 through NLS3 region of L-periaxin with F3 subdomain of ezrin interaction, and the region of L-periaxin (residues 1368-1461) with ezrin (residues 475-557) interaction...Ezrin could inhibit the self-association of L-periaxin, and ezrin overexpression in sciatic nerve injury rats could facilitate the repair of impaired myelin sheath. Therefore, the interaction between L-periaxin and ezrin may adopt a close form to complete protein accumulation and to participate in myelin sheath maintenance.
  • ||||||||||  mazindol (NLS-0) - NLS / 1 Pharma, Nolazol (mazindol CR) / NLS Pharma, viloxazine (SPN-812) / Supernus
    Clinical, Review, Journal:  Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. (Pubmed Central) -  Aug 23, 2020   
    Expert opinion: The authors found 28 pertinent RCTs of compounds acting on a variety of biological targets, including Dasotraline, Viloxazine (SPN-812), Centanafadine SR (CTN SR), OPC-64005, Fasoracetam (NFC-1, AEVI-001), Metadoxine (MDX), Vortioxetine, Tipepidine Hibenzate, Oxytocin, Sativex (delta-9-tetrahydrocannabinol (THC) plus cannabidiol), Mazindol, and Molindone hydrochloride (SPN-810)...However, they may offer comparable or better tolerability. Additionally, agents acting on etiopathophysiological targets disrupted in specific subgroups of patients with ADHD will move forward the pharmacotherapy of ADHD from a "one size fits all" to a "precision medicine" approach.
  • ||||||||||  dexamethasone / Generic mfg., Nolazol (mazindol CR) - NLS / 1 Pharma
    Journal:  PlexinB1 Promotes Nuclear Translocation of the Glucocorticoid Receptor. (Pubmed Central) -  Aug 19, 2020   
    Knockdown of PlexinB1 in prostate cancer cells decreases the levels of glucocorticoid-responsive gene products and antagonizes the decrease in cell motility and cell area of prostate cancer cells upon dexamethasone treatment, demonstrating the functional significance of these findings. These results show that PlexinB1 activation has a role in the trafficking and activation of the nuclear receptor GR and thus may have a role in resistance to androgen deprivation therapy in late stage prostate cancer.
  • ||||||||||  phacetoperane (NLS-3) - NLS / 1 Pharma
    Journal, Immunogenic cell death:  Methods for measuring HMGB1 release during immunogenic cell death. (Pubmed Central) -  Jun 4, 2020   
    Thus, exclusively in the presence of biotin, which liberates HMGB1-SBP-GFP from its nuclear hook, immunogenic cell death (ICD) inducers such as anthracyclines are able to cause the nucleo-cytoplasmic translocation of HMGB1-SBP-GFP. This system facilitates the identification of HMGB1 releasing agents in medium- to high-throughput screening assays.
  • ||||||||||  Nolazol (mazindol CR) - NLS / 1 Pharma, phacetoperane (NLS-3) - NLS / 1 Pharma
    Journal:  Nucleo-cytoplasmic shuttling of Drosophila Hairless/Su(H) heterodimer as a means of regulating Notch dependent transcription. (Pubmed Central) -  Jan 18, 2020   
    We identify NLS3 and NES to be critical for Hairless function...Importantly, we reveal that Su(H) protein strictly follows Hairless protein localization. Together, we propose that shuttling between the nucleo-cytoplasmic compartments provides the possibility to fine tune the regulation of Notch target gene expression by balancing of Su(H) protein availability for Notch activation.
  • ||||||||||  Nolazol (mazindol CR) - NLS / 1 Pharma
    Journal:  Regulation of the Intranuclear Distribution of the Cockayne Syndrome Proteins. (Pubmed Central) -  Oct 24, 2019   
    We reveal herein a complex regulation of CSB targeting that involves three major consensus signals: NLS1 (aa467-481), which directs nuclear and nucleolar localization in cooperation with NoLS1 (aa302-341), and NLS2 (aa1038-1055), which seemingly optimizes nuclear enrichment...Whereas assembly of CSB at sites of DNA damage in the nucleolus was not affected by RNA polymerase I inhibition, stable retention at these sites of presumed repair was abrogated. Our studies reveal a multi-faceted regulation of the intranuclear dynamics of CSA and CSB that plays a role in mediating their cellular functions.
  • ||||||||||  NLS-11 - NLS / 1 Pharma
    Nurse Led Sedation: The Clinical and Echocardiographic Outcomes of the 7-Year Emory Experience () -  Oct 1, 2019 - Abstract #TCT2019TCT_220;    
    Background Our center has developed protocols for nurse-led sedation (NLS) in which nonanesthetist heart team nurses directly provide sedation with fentanyl and midazolam...Mean gradients were similar between groups (NLS 11.3 ± 46 mm Hg vs. MAC 11.8 ± 5.0 mm Hg; p = 0.47)...There are no clinically significant differences in post-deployment hemodynamic status or valve area with NLS compared with anesthetist-led moderate sedation. NLS is associated with significantly shorter procedure room time and contrast volume than anesthetist-led moderate sedation.
  • ||||||||||  phacetoperane (NLS-3) - NLS / 1 Pharma
    Journal:  Identification of pharmacological agents that induce HMGB1 release. (Pubmed Central) -  Jul 17, 2019   
    ...For this, we took advantage of the "retention using selective hooks" (RUSH) system in which a streptavidin-NLS3 fusion protein was used as a nuclear hook to sequestrate streptavidin-binding peptide (SBP) fused with HMGB1 and green fluorescent protein (GFP)...These agents induced ICD through a panoply of distinct mechanisms. Their effective action was confirmed by multiple methods monitoring nuclear, cytoplasmic and extracellular HMGB1 pools, both in cultured human or murine cells, as well as in mouse plasma.
  • ||||||||||  Nolazol (mazindol CR) - NLS / 1 Pharma
    Clinical, Journal:  Early Cholangitis after Portoenterostomy in Children with Biliary Atresia. (Pubmed Central) -  Jul 3, 2019   
    ...The frequency and nature of these episodes were characterized, and the outcome of PE and NLS 1 year after PE was calculated...In our series, cholangitis occurred in most children who cleared jaundice. Furthermore, the 1-year NLS of children who developed cholangitis was 33%.